HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
about
Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomesFragment-Based Screen against HIV ProteaseSimple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutationsMinority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacyX4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHIHIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirsRecent HIV-1 infection contributes to the viral diffusion over the French territory with a recent increasing frequencyProlonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencingHighly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in JapanImpact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected childrTransmitted drug resistance in nonsubtype B HIV-1 infection.Minority variants of drug-resistant HIV.Prevalence and virologic consequences of transmitted HIV-1 drug resistance in UgandaPrimary drug resistance in South Africa: data from 10 years of surveys.Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infectionPersistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease OnsetSuppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection.Transmission networks of drug resistance acquired in primary/early stage HIV infection.Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcomeSpatiotemporal dynamics of HIV-1 transmission in France (1999-2014) and impact of targeted prevention strategies.Evolutionary pathways of transmitted drug-resistant HIV-1.The Genotyping Resistance Profile of the Pol Gene Detected in Blood of Newly Diagnosed HIV-Positive Men Is Durably Archived in the Gut Whatever the Time of Initiation of cART.Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.Persistence of HIV drug resistance among South African children given nevirapine to prevent mother-to-child-transmission.Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of HypermutationFIV establishes a latent infection in feline peripheral blood CD4+ T lymphocytes in vivo during the asymptomatic phase of infectionA cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia.The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in PortugalTransmission cluster of multiclass highly drug-resistant HIV-1 among 9 men who have sex with men in Seattle/King County, WA, 2005-2007.The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing first-line treatment regimen selection.Characterization of HIV-1 Near Full-Length Proviral Genome Quasispecies from Patients with Undetectable Viral Load Undergoing First-Line HAART Therapy.Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations.Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC+ CD4+ cell levels: a surrogate marker candidate of HIV-induced intestinal damage.Evaluation of HIV-1 resistance to antiretroviral drugs among 150 patients after six months of therapeutic interruptionTransmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings
P2860
Q26851997-B1028880-A238-4FAF-B4A9-499F5B3C2DEFQ27663595-28D20959-801B-4BF3-BA1A-037CC449656AQ28469253-061E1FF3-F5C6-4DA3-8326-61DE589B0C63Q28473296-A8D0C588-0020-4AB6-9AC4-C1F4F0982C3BQ28476667-829B6E53-F5ED-4541-9E8F-DB788CE44D9AQ28477500-ED4EE433-F118-4006-A4C3-D80EB8FBCF96Q28480667-E4E7ED0C-286D-4549-9EF5-EF1D935497AEQ28484064-DF106186-6D21-4EDB-AD35-B8B66D59F29EQ28537608-148F26FA-9129-4CAE-B5C9-F99BEB1FC35BQ33267065-7462B819-80CD-4BFE-99D7-FE21C3CA51B1Q33567164-6E200F63-2AF8-4AF2-9B06-0F4FBCE7CDA2Q34047780-5B44D37B-38DD-42F9-9729-7B93943CE285Q34116836-22FB4021-E409-4231-9D54-F150DE64528DQ34129300-72D4392E-2F97-47A6-8EDF-EEC02293904FQ34190296-DD37DC03-A069-4533-BA2C-6AEDAAC95FBFQ34677368-9B33A936-4835-4641-9CC3-BFCEC23E11E5Q35913936-28B111B8-1997-459F-953A-EB5B8B43AFD7Q36100333-F91AC647-7A79-422A-B56A-47A18570D9F0Q36315555-272E0A40-3434-4A16-93B7-E743AE45C1A5Q36798007-B7F5170D-AD7C-4DAF-9B05-7CDB9DFFD4B3Q36928649-4365584B-BCA6-4CBF-A089-ADBBF39BB17AQ37115372-74144AF0-BA48-4654-BACB-87E740B8BFEAQ37373179-AB35EAFE-7A19-44F6-AC0D-DFC3E2E11DF0Q37661745-11C6E4CF-3F0E-4070-9D44-263A3BAC49E9Q37866540-D39882F5-9F87-4A8E-8F66-B27AFF0EBD39Q38375046-21F7CD95-F8D6-4614-8832-FA756A7CB466Q39980493-8397C500-7E60-4283-8F32-240D59921666Q40291462-8BC71E71-B9D5-4146-B1BB-FF137FE7FE3DQ40715404-040D11F5-76F8-4A49-B8AE-DBBA1F3ABB07Q41853004-033B01A8-AACA-485E-831C-83D50FA65201Q42245563-5BCC35D3-CF59-404A-9F9F-5BBD75DB9D15Q42742963-7F281554-2092-4573-B5A5-A8A8B52419F0Q43239908-DEDA1DCE-7611-468A-ACFC-954294EB7A6DQ44085485-A7219904-54B3-435E-84C0-F1A4AA78EEA2Q47140686-C5FA0F78-F6BE-45BB-B165-85DFA317815AQ54482814-AA8EA311-B31B-4506-90B1-608D18314387Q55605404-2B1C0D94-AB08-42F3-9F0C-CEA19DACB913Q57564324-53659278-92F7-4EBC-BBB0-3A63D23DCE4CQ57880269-25F1CDC9-448B-47E9-ADF4-1F41D8B35F91
P2860
HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
HIV-1 resistant strains acquir ...... t for lengthy periods of time.
@en
type
label
HIV-1 resistant strains acquir ...... t for lengthy periods of time.
@en
prefLabel
HIV-1 resistant strains acquir ...... t for lengthy periods of time.
@en
P2093
P1433
P1476
HIV-1 resistant strains acquir ...... t for lengthy periods of time.
@en
P2093
Catherine Tamalet
Christiane Deveau
Cécile Goujard
French PRIMO Cohort Study Group (ANRS CO 06)
Isabelle Pellegrin
Jade Ghosn
Jean-Paul Viard
Julie Galimand
Laurence Meyer
Marie-Laure Chaix
P304
P356
10.1097/01.AIDS.0000199820.47703.A0
P407
P577
2006-01-01T00:00:00Z